Betaxon is a drug owned by Alcon Pharmaceuticals Ltd. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 30, 2014. Details of Betaxon's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US5540918 (Pediatric) | Use of certain anionic surfactants to enhance antimicrobial effectiveness of ophthalmic compositions |
Jan, 2014
(10 years ago) |
Expired
|
| US5540918 | Use of certain anionic surfactants to enhance antimicrobial effectiveness of ophthalmic compositions |
Jul, 2013
(11 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Betaxon is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Betaxon's family patents as well as insights into ongoing legal events on those patents.
Betaxon's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Betaxon's generic launch date based on the expiry of its last outstanding patent is estimated to be Jan 30, 2014 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Betaxon Generics:
There are no approved generic versions for Betaxon as of now.
About Betaxon
Betaxon is a drug owned by Alcon Pharmaceuticals Ltd. Betaxon uses Levobetaxolol Hydrochloride as an active ingredient. Betaxon was launched by Alcon Pharms Ltd in 2000.
Approval Date:
Betaxon was approved by FDA for market use on 23 February, 2000.
Active Ingredient:
Betaxon uses Levobetaxolol Hydrochloride as the active ingredient. Check out other Drugs and Companies using Levobetaxolol Hydrochloride ingredient
Dosage:
Betaxon is available in suspension/drops form for ophthalmic use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 0.5% BASE | SUSPENSION/DROPS | Discontinued | OPHTHALMIC |